Yoshihito Yokoyama

Dr. Yoshihito Yokoyama


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2003 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YYYoshihito Yokoyama
Yoshihito Yokoyama
DCD. Stephen Charnock-Jones
D. Stephen Charnock-Jones
DLD Licence
D Licence
AYA Yanaihara
A Yanaihara
JHJ M Hastings
J M Hastings
SSS K Smith
S K Smith
We assessed the presence of vascular endothelial growth factor (VEGF)-C, VEGF-D and their receptor VEGFR-3 by immunohistochemistry in 59 epithelial ovarian carcinomas, 11 borderline tumours and 20 benign cystadenomas. VEGF-C and VEGF-D were generally expressed in tumour cells and also in endothelia adjacent to tumour nests which showed a strong staining for them. VEGFR-3 was expressed in lymphatic and vascular endothelial cells adjacent to tumour nests. Immunoreactivity was significantly more frequent as lesions progressed from a benign tumour to advanced carcinoma. A strong correlation was found between VEGF-C and VEGF-D detected in carcinoma and VEGFR-3 detected in neighbouring endothelial cells. Increased expression of VEGF-C, VEGF-D and VEGFR-3 was significantly associated with lymph node metastasis and peritoneal metastasis outside the pelvis. There was a significant correlation between the high levels of VEGF-C and VEGF-D proteins, and poor survival. The presence of VEGF-D was an independent prognostic indicator by multivariate analysis. We conclude that VEGF-C, VEGF-D and VEGFR-3 play an important role in lymphatic spread and intraperitoneal tumour development in ovarian carcinoma. Since VEGF-D was found to be an independent predictor of poor outcome, its measurement, together with other prognostic markers may improve prospective identification of patients with a poor prognosis.

1 April 2007 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YYYoshihito Yokoyama
Yoshihito Yokoyama
BXBing Xin
Bing Xin
TSTatsuhiko Shigeto
Tatsuhiko Shigeto
MUMika Umemoto
Mika Umemoto
AKAkiko Kasai-Sakamoto
Akiko Kasai-Sakamoto
HMHideki Mizunuma
Hideki Mizunuma
Recent reports have shown that peroxisome proliferator–activated receptor (PPAR)α ligands reduce growth of some types of malignant tumors and prevent carcinogenesis. In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for PPARα on growth of ovarian malignancy, in in vivo and in vitro experiments using OVCAR-3 and DISS cells derived from human ovarian cancer and aimed to elucidate the molecular mechanism of its antitumor effect. CA treatment significantly suppressed the growth of OVCAR-3 tumors xenotransplanted s.c. and significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared with control. CA also dose-dependently inhibited cell proliferation of cultured cell lines. CA treatment increased the expression of carbonyl reductase (CR), which promotes the conversion of prostaglandin E2 (PGE2) to PGF2α, in implanted OVCAR-3 tumors as well as cultured cells. CA treatment decreased PGE2 level as well as vascular endothelial growth factor (VEGF) amount in both of OVCAR-3–tumor and DISS-derived ascites. Reduced microvessel density and induced apoptosis were found in solid OVCAR-3 tumors treated by CA. Transfection of CR expression vector into mouse ovarian cancer cells showed significant reduction of PGE2 level as well as VEGF expression. These results indicate that CA produces potent antitumor effects against ovarian cancer in conjunction with a reduction of angiogenesis and induction of apoptosis. We conclude that CA could be an effective agent in ovarian cancer and should be tested alone and in combination with other anticancer drugs. [Mol Cancer Ther 2007;6(4):1379–86]

9 May 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
YYYoshihito Yokoyama
Yoshihito Yokoyama
TMT Moriya
T Moriya
TTT Takano
T Takano
TST Shoji
T Shoji
OTO Takahashi
O Takahashi
HMH Mizunuma
H Mizunuma
We investigated the long-term prognosis of borderline ovarian tumours and determined risk factors for recurrence. One hundred and twenty-one borderline ovarian tumours treated between 1994 and 2003 at the participating institutions in the Tohoku Gynecologic Cancer Unit were retrospectively investigated for clinical stage, histopathological subtype, surgical technique, postoperative chemotherapy, the presence or absence of recurrence, and prognosis. The median follow-up period was 57 months (1–126 months). One hundred and nine cases (90.6%) were at clinical stage I. The histopathological subtypes consisted of 91 cases of mucinous tumour (75.2%), 27 cases of serous tumour (22.3%), and three cases of endometrioid tumour. Conservative surgery was used in 53 cases (43.8%), radical surgery in 68 cases (56.2%), a staging laparotomy in 43 cases (35.5%), and postoperative adjuvant therapy in 30 cases (24.8%). Recurrence was found in eight cases, but no tumour-related deaths were reported. Although no significant difference in disease-free survival rate was seen between different clinical stages, the difference in disease-free survival rate between serous and nonserous (mucinous and endometrioid) types was significant (P<0.05). The 10-year disease-free survival rate was 89.1% for the radical surgery group and 57.4% for the conservative surgery group – this difference was significant (P<0.05). In the conservative surgery group, cystectomy and serous tumour were independent risk factors for recurrence. Although recurrence was observed, the long-term prognosis of borderline ovarian tumour was favourable, without tumour-related deaths. Considering the favourable prognosis, conservative surgery can be chosen as far as the patient has a nonserous tumour and receive adnexectomy. However, in cases of serous type and/or receiving cystectomy special care should be given as relative risk rates of recurrence elevate by 2–4-folds.

20 June 2007 in Cancer
Verified
Journal Article
Open access
PDF file
BXBing Xin
Bing Xin
YYYoshihito Yokoyama
Yoshihito Yokoyama
TSTatsuhiko Shigeto
Tatsuhiko Shigeto
MFMasayuki Futagami
Masayuki Futagami
HMHideki Mizunuma
Hideki Mizunuma
BACKGROUND.: It was recently reported that high expression of peroxisome proliferator‐activated receptor γ (PPARγ) and low expression of cyclooxygenase‐2 (COX‐2) might be involved in the inhibition of ovarian tumor progression and confirmed that PPARγ activation could suppress COX‐2 expression via the nuclear factor‐κB pathway in ovarian cancer cells.METHODS.: The current study investigated whether meloxicam, a selective COX‐2 inhibitor, and ciglitazone, a ligand for PPARγ, inhibit the growth of human ovarian cancer cell lines and aimed to elucidate the molecular mechanism of their antitumor effect. Tumor growth and survival were examined in female nu/nu mice xenografted with subcutaneous OVCAR‐3 tumors or with intraperitoneal DISS tumors and treated with meloxicam (162 ppm in diet, every day) or ciglitazone (15 mg/kg intraperitoneally once a week).RESULTS.: Both meloxicam and ciglitazone treatments significantly suppressed the growth of OVCAR‐3 tumors xenotransplanted subcutaneously and significantly prolonged the survival of mice with malignant ascites derived from DISS cells as compared with controls. Meloxicam treatment decreased COX‐2 expression in tumors by 2.5‐fold compared with that observed in untreated tumors. Although ciglitazone treatment did not alter COX‐2 expression in tumors, it reduced the expression of microsomal prostaglandin (PG) E synthase, which converts COX‐derived PGH2 to PGE2. Both meloxicam and ciglitazone decreased PGE2 levels in serum as well as in ascites. Reduced microvessel density and induced apoptosis were found in solid OVCAR‐3 tumors treated with either meloxicam or ciglitazone.CONCLUSIONS.: These results indicate that both meloxicam and ciglitazone produce antitumor effects against ovarian cancer in conjunction with reduced angiogenesis and induction of apoptosis. Cancer 2007; 110:791–800. © 2007 American Cancer Society.

1 January 2014 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YYYoshihito Yokoyama
Yoshihito Yokoyama
YMYoko Matsushita
Yoko Matsushita
TSTatsuhiko Shigeto
Tatsuhiko Shigeto
MFMasayuki Futagami
Masayuki Futagami
HMHideki Mizunuma
Hideki Mizunuma
Yokoyama Y, et al. J Gynecol Oncol. 2014 Jan;25(1):58-63. https://doi.org/10.3802/jgo.2014.25.1.58

1 January 2014 in Molecular Pain
Verified
Journal Article
Open access
YMYukiko Matsumura
Yukiko Matsumura
YYYoshihito Yokoyama
Yoshihito Yokoyama
HHHachidai Hirakawa
Hachidai Hirakawa
TSTatsuhiko Shigeto
Tatsuhiko Shigeto
MFMasayuki Futagami
Masayuki Futagami
HMHideki Mizunuma
Hideki Mizunuma
Background: This study aimed to evaluate the prophylactic effect of goshajinkigan (GJG) on paclitaxel (PTX)-induced neuropathy and to elucidate the mechanism of action. Results: There was a time-dependent irreversible decrease in pain threshold in PTX group. In PTX/GJG group, pain threshold showed changes in the same level as control. Electron microscope showed that although the ganglion cells of control and PTX/GJG groups were normal, degeneration of the nucleus and swelling of the mitochondria were observed in PTX group. Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly increased compared with that in control and PTX/GJG groups. In TRPV4 knock-out mice, no PTX-induced hyperalgesia was observed, and there was no significant difference in pain threshold between the 3 groups. Conclusions: These results showed that PTX induced hyperalgesia by enhancing TRPV4 expression, and suggested that GJG might alleviate hyperalgesia by preventing degeneration of the ganglion cells and suppressing TRPV4 expression.